Lhasa Limited shared knowledge shared progress
Publications

Session 3 - A pharmaceutical regulator’s view on the utility of adverse outcome pathways for carcinogenicity assessment - Slides

pdf fileJones D;

Guest speaker, David Jones, Expert Pharmaco-Toxicologist at MHRA, gave this presentation as part of session 3 of Lhasa's 2020 AOP themed virtual symposium.

The session title was 'The potential utility of AOPs in the future of regulatory decision-makingand was the third in a series of 4 webinars that made up the symposium. 

This publication is a copy of David's presentation slides. 

Download

© 2020 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Thanks to QuestionPro's generosity, we now have survey software that powers our data intelligence.